# W0265-103: A Single-Center, Evaluator-Blinded, Randomized, Placebo Controlled, Phase 1 Clinical Trial Evaluating The Phototoxic Potential Of Topically Applied Clindamycin 1.0% - Tretinoin 0.025% Gel (Ct Gel) In Healthy Volunteers

> **NCT01929278** · PHASE1 · COMPLETED · sponsor: **Stiefel, a GSK Company** · enrollment: 37 (actual)

## Conditions studied

- Acne Vulgaris

## Interventions

- **DRUG:** CT Gel (clindamycin 1% and tretinoin 0.025%)
- **OTHER:** Vehicle gel patch
- **OTHER:** Blank patch

## Key facts

- **NCT ID:** NCT01929278
- **Lead sponsor:** Stiefel, a GSK Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12-08
- **Primary completion:** 2008-12-19
- **Final completion:** 2008-12-19
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2017-07-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01929278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01929278, "W0265-103: A Single-Center, Evaluator-Blinded, Randomized, Placebo Controlled, Phase 1 Clinical Trial Evaluating The Phototoxic Potential Of Topically Applied Clindamycin 1.0% - Tretinoin 0.025% Gel (Ct Gel) In Healthy Volunteers". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT01929278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*